09/938702

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE 531 Rec'd P

Art Unit: Not yet assigned

13 SEP 200°

In re application of: Berger and Del Castillo

Application No. Not yet assigned

Filed: Herewith

For: A NOVEL CHIMERIC PROTEIN FOR PREVENTION AND TREATMENT OF HIV

INFECTION

Examiner: Not yet assigned

Date: September 13, 2001

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(b)(2)

BOX PCT COMMISSIONER FOR PATENTS WASHINGTON, DC 20231

Sir:

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants filed this Information Disclosure Statement ("IDS") within three months of the date of entry of the national stage as set forth in § 1.491 in an international application. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this Information Disclosure Statement, please see the attached transmittal sheet for Deposit Account authority

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600

121 S.W. Salmon Street Portland, Oregon 97204 Telephone: (503) 226-7391

Facsimile: (503) 228-9446

Tanya M. Harding, Ph.D. Registration No. 42,630

i